CAMLINFINECamlin Fine Sciences Limited
Chemicals · Specialty Chemicals · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include basic ingredients, such as tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), and Ascorbyl Palmitate (ASP); aroma ingredients, including vanillin and ethyl vanillin, natural vanillin, and some of its combinations; performance chemicals that include Hydroquinone (HQ), Catechol (CAT), Monomethyl Ether of HQ (MEHQ), tert butylcatechol (TBC), Guaiacol, and Veratrole; and health and wellness products comprising algae based products, such as Omega 3 fatty acids. It sells its prodycrts under the Xtendra, Nasure, Ezential, adorr, Dinamic, and Biosus brands. The company's products are used in food and beverage, pet food and rendering, animal nutrition, petrochemical, nutrition and health, biofuel, agrochemical, pharmaceutical, polymers, fragrance and flavor, and dyes and pigments industries. The company was formerly known as Camlin Fine Chemicals Ltd. and changed its name to Camlin Fine Sciences Limited in August 2011. Camlin Fine Sciences Limited was founded in 1931 and is headquartered in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on CAMLINFINE — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 34/100)
- • ROE: 2.7%
- • ROCE: 2.0%
- • RSI: 36
- • Price vs EMA21: below
Bull case
- • Revenue growth: 22.7% YoY
- • Profit growth: 119.9% YoY
- • Debt/Equity: 0.72
- • MACD: bullish
Bear case
- • ROE: 2.7%
- • ROCE: 2.0%
- • RSI: 36
- • Price vs EMA21: below
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Momentum is fading versus the broader market
- • ROE: 2.7%
- • ROCE: 2.0%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹4.14). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.